After the body is traumatized, the transgene carried by the transplanted transgenic cells has a very large stimulating effect on the central nervous system. Pathological features occur around the injured area during spinal cord injury. In order to achieve a complete therapeutic effect, the transgene not only has an effect on the injured part, but also on the surrounding area of ​​the injury. Two transgenes such as vascular endothelial growth factor (VEGF) and glial cell-derived neurotrophic factor (GDNF) have been shown to contribute to maintaining the viability of spinal cord cell populations including motor neurons. VEGF promotes nerve formation, axon growth, and rapid proliferation of astrocytes, neural stem cells, and Schwann cells. GDNF can reduce apoptosis and tissue degeneration, promote the expression of neurofilament protein, calcitonin-related gene peptide (CGRP) and promote the growth of related protein 43. In this study, the researchers selected human umbilical cord blood mononuclear cells (UCB-MCs), which are easily produced and safe, have lower immunogenicity and promote nerve regeneration. Umbilical cord blood cells can be converted into two factors, VEGF and GDNF. VEGF and GDNF can act through different receptors and channels, and the researchers hypothesized that the simultaneous action of these two therapeutic genes would promote synergistic neuroprotective effects. The researchers used rats to make a spinal cord injury model. "We examined the effectiveness of tissue retention construction, the severity of glial scars, the extent of axonal regeneration, motor recovery, and the expression of recombinant VEGF and GNDF in vitro and in vivo. Situation," Yana Mukhamedshina said. The experimental results indicate that the adenoviral vector encodes VEGF and GDNF and converts them into UCB-MCs, which are effective and stable after transplantation. The researchers concluded that transgenic human cord blood cells are a promising approach to improve post-traumatic regeneration.
Pharmaceuticals
finish product is the main product of Ningbo Voice Biochemic Co., Ltd..
The product line covers almost all the dosage forms, including tablets,
capsules, small volume injections, infusions, eye/ear drops, creams and
ointments, powder for injections and Aerosols. All finish products are
produced in the GMP standard workshop.
Our
pharmaceutical finish products are registered in the countries of Asia,
Africa and South America under our own brand: VOICE, which is have won a
high reputation in the marketing countries. Together with our own trade
mark, the packaging of all pharmaceuticals finish products are well
designed according to the requirement of different market.. Cardiovascular Drugs,Antipyretic Analgesics,Antiviral And Antibiotics,Finished Pharmaceutical Products NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com